By integrating metabolic modulation with established treatments like TNF-α or IL-17 inhibitors, clinicians may break the vicious cycle between AT and psoriatic inflammation, ultimately improving both skin and systemic health outcomes. The gene discussed is IL17A; the disease is ataxia telangiectasia.